Search clinical trials for: Euvolemic

Total 22 results

University Hospital, Basel, Switzerland
Centre Hospitalier Universitaire Vaudois; Luzerner Kantonsspital

Recruiting

Effects of the SGLT2 Inhibitor Empagliflozin in Patients With Euvolemic and Hypervolemic Hyponatremia (EMPOWER)

Liver Failure | Hyponatremia | Kidney Failure | SIADH

Switzerland
Hospital San Carlos, Madrid

Completed

Changes in Serum Creatinine Levels Can Help Distinguish Hypovolemic From Euvolemic Hyponatremia

Hyponatremia | Hypovolemia | SIADH

Spain
Beth Israel Deaconess Medical Center
Baxter Healthcare Corporation

Suspended

Observational Study to Evaluate Peripheral IntraVenous Analysis (PIVA) in Euvolemic, Hypovolemic, and Hypervolemic Emergency Department Patients (PIVA)

Septic Shock | Infection | Congestive Heart Failure | Hypovolemia | Acute Heart Failure | Hypervolemia

United States
Otsuka Pharmaceutical Development & Commercialization...
Syneos Health

Terminated

An Extension Follow-up Trial to Evaluate the Long-term Safety of Children and Adolescent Participants With Euvolemic or Hypervolemic Hyponatremia

Hyponatremia

Belgium, Spain, United States, United Kingdom, Italy, Germany, Czechia, Romania
Korea Otsuka Pharmaceutical Co., Ltd.

Completed

Samsca Post Marketing Surveillance Study (Samsca PMS)

Hypervolemic and Euvolemic Hyponatremia

Korea, Republic of
NYU Langone Health

Withdrawn

Fractional Urate Excretion in Nonedematous Hyponatremia

SIADH | Cerebral Hyponatremia | Cerebral Salt-wasting Syndrome | Reset Hypothalamic Osmostat

United States
Otsuka Pharmaceutical Development & Commercialization...
Syneos Health

Terminated

Study of the Safety and Effectiveness of SAMSCA® (Tolvaptan) in Children and Adolescents With Euvolemic or Hypervolemic Hyponatremia

Hyponatremia

United States, United Kingdom, Italy
NYU Langone Health
Otsuka America Pharmaceutical

Terminated

Tolvaptan to Reduce Length of Stay in Hospitalized Patients With Cirrhosis and Hyponatremia

Hyponatremia

United States
Otsuka Pharmaceutical Development & Commercialization...

Withdrawn

A Trial of Tolvaptan in Children and Adolescent Subjects With Euvolemic and Hypervolemic Hyponatremia

Hyponatremia
Cumberland Pharmaceuticals

Terminated

A Study to Assess the Efficacy, Safety and Pharmacokinetics of Intravenous Conivaptan (Vaprisol®) in Pediatric Subjects With Euvolemic or Hypervolemic Hyponatremia

Hyponatremia

United States, Colombia
Otsuka America Pharmaceutical
Registrat-Mapi

Completed

Hyponatremia Registry for Patients With Euvolemic and Hypervolemic Hyponatremia (HN Registry)

Euvolemic Hyponatremia | Hypervolemic Hyponatremia

United States, United Kingdom, Germany
Columbia University
Astellas Pharma Inc

Withdrawn

Safety and Efficacy of Conivaptan for the Correction of Hyponatremia in Neurological Patients

Hyponatremia

United States
Otsuka Pharmaceutical Development & Commercialization...

Terminated

Effects of Tolvaptan vs Fluid Restriction in Hospitalized Subjects With Dilutional Hyponatremia (SALACIA)

Hyponatremia | Inappropriate ADH Syndrome | Dilutional Hyponatremia

United States
Cumberland Pharmaceuticals

Completed

A Study of Multiple Dosing Regimens of IV Conivaptan in Subjects With Euvolemic or Hypervolemic Hyponatremia

Hyponatremia | Euvolemia | Hypervolemia

Israel, United States, India
Cumberland Pharmaceuticals

Terminated

Safety and Efficacy of Conivaptan in Hyponatremic Patients With Symptomatic Acute Decompensated Heart Failure (ADHF) (CONVERT-H)

Acute Decompensated Heart Failure | Hyponatremia

India
Cumberland Pharmaceuticals

Completed

Study of Efficacy & Safety for 3 Infusion Regimens of IV Conivaptan in Subjects With Euvolemic or Hypervolemic Hyponatremia

Hyponatremia

United States, India
Cumberland Pharmaceuticals
Parke-Davis

Completed

Study of Efficacy & Safety of Oral YM087 in Subjects With Euvolemic or Hypervolemic Hyponatremia

Hyponatremia

Poland, United Kingdom, Germany, Spain, Belgium, France, Netherlands, Italy, Finland
Cumberland Pharmaceuticals

Completed

An Open-Label Study of YM087 (Conivaptan) in Patients With Euvolemic or Hypervolemic Hyponatremia

Hyponatremia

South Africa, United States, Israel
Cumberland Pharmaceuticals
Astellas Pharma US, Inc.

Completed

Study of IV YM087 to Assess Efficacy and Safety in Patients With Euvolemic or Hypervolemic Hyponatremia

Hyponatremia

United States, South Africa, Israel, Canada
CardioKine Inc.
Biogen; Cardiokine Biopharma, LLC

Completed

Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Oral Lixivaptan Capsules in Subject With Euvolemic Hyponatremia

Hyponatremia With Normal Extracellular Fluid Volume

United States, Canada, Germany, India, Poland, Belgium
CardioKine Inc.
Biogen; Cardiokine Biopharma, LLC

Completed

A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Tolerability of Oral Lixivaptan Capsules in Subjects With Euvolemic Hyponatremia

Euvolemic Hyponatremia

United States, Israel, India, Mexico, Peru, Belgium, Czech Republic, Italy
CardioKine Inc.
Biogen; Cardiokine Biopharma, LLC

Completed

International, Multicenter Study of a Twenty-eight Week, Open-label, Titrated Oral Lixivaptan Administration in Patients With Chronic Hyponatremia: Extension to Studies CK-LX3401, 3405, and 3430

Hyponatremia With Excess Extracellular Fluid Volume | Hyponatremia With Normal Extracellular Fluid Volume

United States

Search clinical trials for: Euvolemic

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Sweden

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations